Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T-cell Therapy and Ipilimumab in Metastatic Melanoma
NCT02027935Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Apr 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Melanoma antigens-specific CD8+ T lymphocytes in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Efficacy of CTL with Anti-CTLA4 at 2 years. Started Jan 2015; status: completed.
02
Drugs
Melanoma antigens-specific CD8+ T lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02027935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027935.